Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

2(50.0%)

Phase 3

1(25.0%)

Phase 2

1(25.0%)

4Total

Phase 1(2)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07377838Phase 3Not Yet Recruiting

Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

Role: lead

NCT06071143Phase 1Recruiting

Safety and Efficacy of KDSTEM Inj. in Patients With Chronic Kidney Disease

Role: lead

NCT04137562Phase 2Active Not Recruiting

Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

Role: lead

NCT03252340Completed

Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

Role: lead

NCT02888704Phase 1Completed

Safety and Efficacy of ADSTEM Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis

Role: lead

All 5 trials loaded